Abstract:The p38 mitogen-activated protein kinase (MAPK) identified in human monocytes represents a potentially attractive therapeutic target for a class of cytokine suppressive anti-inflammatory compounds. However, the limitations of protein therapeutics have stimulated significant research aimed at developing orally bioavailable, small molecular inhibitors of cytokines. In this paper, virtual ligand-based 3D pharmacophore model, CoMFA modelling and molecular docking were employed to identify novel and structurally instinct inhibitors of small molecules. 3D-ligand-based pharmacophore models with four elements for p38 MAPK inhibitors were firstly developed. Following the validation of the pharmacophore models through the test data set, Fischer’s randomization test and CoMFA analysis, the final pharmacophore model generated was found to be highly predictive for identifying p38 inhibitors over drug-like non-inhibitors. Calculated enrichment factor shows 88 % of actives being recovered in the top 7 % of the database, and all actives being recovered in the first 12 % of the database screened, while a true positive rate of 0.09 with a false positive rate of only 0.067 is obtained. The well-validated pharmacophore model was then utilised to screen several databases as a 3D query to retrieve compounds. All hits obtained from database searching were further screened using ADMET filters. Twenty-seven compounds were selected based on high fit values and diverse structures. The molecular docking with the binding site determined by X-ray structures of the protein provides a structure and binding validation for active compounds, which is in agreement with that obtained by the final pharmacophore model. The binding model and mechanism of the compounds are also described.

Docking and 3D-QSAR study on p38α MAP kinase inhibitors

3d-Qsar And Molecular Docking Studies On Fused Pyrazoles As P38 Alpha Mitogen-Activated Protein Kinase Inhibitors

Insight into the Structural Determinants of Imidazole Scaffold-Based Derivatives As P38 MAP Kinase Inhibitors by Computational Explorations

Ligand-based 3D pharmacophore design, virtual screening and molecular docking for novel p38 MAPK inhibitors

3D-QSAR and Docking Studies of 3-Pyridine Heterocyclic Derivatives As Potent PI3K/mTOR Inhibitors

3D-QSAR and Molecular Docking Studies of ATP-competitive Akt Inhibitors with the Scaffold 4-(Piperazin-1-yl)pyrimidine

Pharmacophore modeling and 3D-QSAR analysis of phosphoinositide 3-kinase p110alpha inhibitors.

Evaluation of the Combination Mode and Features of P38 MAPK Inhibitors: Construction of Different Pharmacophore Models and Molecular Docking

Pharmacophore modeling and 3D-QSAR analysis of phosphoinositide 3-kinase p110α inhibitors

Combined 3D-QSAR modeling and molecular docking study on quinoline derivatives as inhibitors of P-selectin.

3D-Qsar and Docking Studies on Pyrrolopyrimidine Derivatives As Lim-Kinase 2 Inhibitors

Action Mechanisms and Structure–activity Relationships of PI3Kγ Inhibitors on the Enzyme: a Molecular Modeling Study

Receptor and ligand-based 3D-QSAR study on a series of pyrazines/pyrrolidylquinazolines as inhibitors of PDE10A enzyme

3D-QSAR Research of Pteridine PI3Kγ Inhibitor

3D-QSAR, Docking, and Molecular Dynamics Simulations Studies on Quinazoline Derivatives As PAK4 Inhibitors

Molecular modeling studies on imidazo[4,5-b]pyridine derivatives as Aurora A kinase inhibitors using 3D-QSAR and docking approaches.

Combined Pharmacophore Modeling, Docking, And 3d-Qsar Studies Of Plk1 Inhibitors

Molecular Docking and 3D-QSAR Research of Biphenyl Carboxylic Acid MMP-3 Inhibitors

3D-QSAR and Docking Study on 3-Benzimidazol-2-ylhydroquinolin-2-one Derivatives As VEGFR-2 Tyrosine Kinase Inhibitors

Integrating Docking Scores, Interaction Profiles and Molecular Descriptors to Improve the Accuracy of Molecular Docking: Toward the Discovery of Novel Akt1 Inhibitors

3D-QSAR and Surflex-dock Study of Pyrimidine Scaffold Compounds As Dual PI3K/mTOR Inhibitors